Grifols, S.A.
NASDAQ:GRFSDrug Manufacturers - General
+$0.03 today
- Market cap
- $7.17B
- Beta
- 1.17
- P/E (TTM)
- 14.7
- EPS (TTM)
- $0.61
- Dividend yield
- 1.67%
Volume 0.59M
Average 0.69M
GRFS Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Grifols, S.A.NASDAQ: GRFS
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue declines year over year
Q2 FY2026 revenue of €1.87B fell 0.9% year over year, behind the -0.2% change in trailing-twelve-month revenue. Sequentially, it rose 8.5% from the prior quarter. Over 3 fiscal years it compounded at +6.0% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of €7.71B (+6.7%) for the fiscal year ending Dec 2026, a step up from the +0.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- €1.87B+8.5% QoQ
- Last fiscal yearDec 2025
- €7.23B+0.2% YoY
- LTMJun 2026
- €7.43B-0.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.9% | +6.1% | +7.1 pp |
| 1 year | +0.2% | +6.7% | +6.5 pp |
| 3-year CAGR | +6.0% | +6.2% | +0.2 pp |
| 5-year CAGR | +5.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
EUR · from the income statement
- Latest · FY2025
- 7.23B EUR
- Year-over-year change
- +0.2%
- 4-year CAGR
- +10.0%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.23B | +0.2% |
| FY2024 | 2024-12-31 | 7.21B | +9.4% |
| FY2023 | 2023-12-31 | 6.59B | +8.7% |
| FY2022 | 2022-12-31 | 6.06B | +22.9% |
| FY2021 | 2021-12-31 | 4.93B | — |
Revenue vs competitors
How GRFS compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -0.2% is the 6th highest of 9, against a peer median of +0.7%.
- Over three fiscal years its annual growth of +6.0% compares with a peer median of +0.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $48.23B USD | +10.0% | +0.5% | |
| LTM Sep 2026 | $20.22B USD | -7.4% | +0.1% | |
| LTM Jun 2026 | €7.43B EUR | -0.2% | +6.0% | |
| LTM Mar 2026 | $2.66B USD | -3.9% | -5.8% | |
| LTM Jun 2026 | $2.59B USD | +1.4% | -2.7% | |
| LTM Jun 2026 | $1.35B USD | +0.4% | +4.5% | |
| LTM Sep 2026 | $1.23B USD | +0.9% | +2.2% | |
| LTM Jun 2026 | $512.28M USD | +8.0% | +49.0% | |
| LTM Jun 2026 | $208.78M USD | -3.3% | -40.5% | |
| Peer median (excluding GRFS) | — | +0.7% | +0.3% | |
Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.93B | 6.06B | 6.59B | 7.21B | 7.23B |
| Cost of Revenue | 2.97B | 3.85B | 4.11B | 4.42B | 4.65B |
| Gross Profit | 1.96B | 2.21B | 2.48B | 2.79B | 2.58B |
| Gross Margin | 39.8% | 36.5% | 37.7% | 38.7% | 35.7% |
| Research & Development | 354.88M | 361.14M | 395.28M | 384.04M | 358.28M |
| Selling, General & Admin | 1.06B | 1.11B | 1.27B | 1.14B | 1.02B |
| Operating Expenses | 1.37B | 1.43B | 1.7B | 1.6B | 1.39B |
| Depreciation & Amortization | 359.77M | 410.98M | 446.42M | 437.9M | 432.24M |
| EBITDA | 944.03M | 1.19B | 1.17B | 1.48B | 1.62B |
| EBITDA Margin | 19.1% | 19.7% | 17.7% | 20.6% | 22.5% |
| Operating Income | 595.06M | 782.44M | 782.32M | 1.19B | 1.19B |
| Operating Margin | 12.1% | 12.9% | 11.9% | 16.5% | 16.4% |
| Interest Income | 11.55M | 33.86M | 62.43M | 48.05M | 32.66M |
| Interest Expense | 233.81M | 444.54M | 516.06M | 773.16M | 600.33M |
| Other Income / Expenses | (244.61M) | (444.42M) | (575.3M) | (748.02M) | (596.49M) |
| Income Before Tax | 350.45M | 338.01M | 207.02M | 444M | 590.73M |
| Pre-Tax Margin | 7.1% | 5.6% | 3.1% | 6.2% | 8.2% |
| Income Tax Expense | 85.13M | 90.11M | 43.35M | 231.19M | 110.46M |
| Net Income | 188.73M | 185.04M | 42.32M | 156.92M | 386.13M |
| Net Margin | 3.8% | 3.1% | 0.6% | 2.2% | 5.3% |
| EPS (Basic) | 0.27 | 0.31 | 0.09 | 0.23 | 0.57 |
| EPS (Diluted) | 0.27 | 0.31 | 0.09 | 0.23 | 0.57 |
| Weighted Avg Shares | 681.56M | 679.81M | 679.76M | 680.02M | 680.58M |
| Weighted Avg Shares (Diluted) | 681.56M | 679.81M | 679.76M | 680.02M | 680.58M |
Grifols, S.A.
NASDAQ:GRFS
Intrinsic Alpha fair value
Locked
Current Price
$8.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.